Taysha gene therapies provides clinical updates for investigational programs tsha-120 in giant axonal neuropathy (gan) and tsha-102 in rett syndrome at r&d day

Company views that results of comprehensive data analysis of tsha-120 and development of disease progression model (dpm) address u.s. food and drug administration (fda) feedback regarding the effort-dependent nature of mfm32 as primary endpoint in an unblinded study and heterogeneity of gan; taysha plans to review potential regulatory pathway for tsha-120 at a formal meeting with the fda expected in q3 2023
TSHA Ratings Summary
TSHA Quant Ranking